Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

Keyphrases

• Ulcerative Colitis 100%
• Tofacitinib 100%
• Global Clinical Trial 100%
• Twice Daily 50%
• Herpes Zoster Infection 40%
• Adverse Events 20%
• Placebo 20%
• Moderate to Severe 20%
• Non-melanoma Skin Cancer 20%
• Severe Ulcerative Colitis 20%
• Malignancy 10%
• Serious Infection 10%
• Small Molecule Inhibitors 10%
• Safety Profile 10%
• Biological Agents 10%
• Treatment Group 10%
• Follow-up Time 10%
• Incidence Rate 10%
• Major Adverse Cardiovascular Events 10%
• Dose-response Relationship 10%
• Induction Studies 10%
• Maintenance Studies 10%
• Opportunistic Infections 10%
• As(III) 10%
• Safety Analysis 10%
• Rheumatoid Arthritis 10%
• Integrated Safety Analysis 10%
• Maintenance Phase 10%
• Intestinal Perforation 10%
• Oral Small Molecules 10%
• Long-term Extension Study 10%
• Years of Exposure 10%
• 2-phase 10%
• Induction Period 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Ulcerative Colitis 100%
• Tofacitinib 100%
• Herpes Zoster 40%
• Adverse Event 20%
• Placebo 20%
• Non Melanoma Skin Cancer 20%
• Infection 10%
• Biological Product 10%
• Opportunistic Infection 10%
• Rheumatoid Arthritis 10%
• Digestive System Perforation 10%
• Cardiovascular Disease 10%
• Inflammatory Arthritis 10%